Details for New Drug Application (NDA): 074619
✉ Email this page to a colleague
NDA 074619 describes GLIPIZIDE, which is a drug marketed by Aurobindo Pharma, Endo Operations, Norvium Bioscience, Unique, Watson Labs, Zydus Pharms, Accord Hlthcare, Aiping Pharm Inc, Ani Pharms, Apotex, Aurobindo Pharma Usa, Barr Labs Inc, Chartwell Rx, Oxford Pharms, Rubicon, Sun Pharm Inds Inc, Watson Labs Teva, Epic Pharma Llc, Esjay Pharma, Heritage, Teva Pharms, and Zydus Pharms Usa Inc, and is included in twenty-six NDAs. It is available from thirty-six suppliers. Additional details are available on the GLIPIZIDE profile page.
The generic ingredient in GLIPIZIDE is glipizide; metformin hydrochloride. There are eighteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the glipizide; metformin hydrochloride profile page.
The generic ingredient in GLIPIZIDE is glipizide; metformin hydrochloride. There are eighteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the glipizide; metformin hydrochloride profile page.
Summary for 074619
| Tradename: | GLIPIZIDE |
| Applicant: | Barr Labs Inc |
| Ingredient: | glipizide |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 074619
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 5MG | ||||
| Approval Date: | Apr 4, 1997 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 10MG | ||||
| Approval Date: | Apr 4, 1997 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
